1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Mental Health Market Trends
  5. > Global Schizophrenia Partnering 2010-2015

Global Schizophrenia Partnering 2010-2015

  • July 2015
  • -
  • Currentpartnering
  • -
  • 100 pages

The report will be delivered in PDF format within 3 working days of receipt of order. If print or CD-Rom version purchased, the report will be sent by courier using express service.

The Schizophrenia Partnering 2010-2015 report provides understanding and access to the schizophrenia partnering deals and agreements entered into by the worlds leading healthcare companies.

Trends in schizophrenia partnering deals
Top schizophrenia deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type

The Schizophrenia Partnering 2010-2015 provides understanding and access to the schizophrenia partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides an analysis of schizophrenia partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors schizophrenia technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.

This data driven report contains over 80 links to online copies of actual schizophrenia deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.

The initial chapters of this report provide an orientation of schizophrenia partnering trends.

Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in partnering since 2010, including a summary of deals by industry sector, stage of development, deal type, and technology type.

Chapter 3 provides an overview of the average deal terms since 2010. The chapter includes deals with a stage of development announced by headline value, upfront value, milestone value and royalty rate. Numerous tables outline financial trends.

Chapter 4 provides an overview of the most active dealmakers, top dealmakers by value, active big pharma and big biotech dealmakers including contract documents where available.

Chapter 5 provides a comprehensive directory of partnering deals signed and announced since 2010. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of schizophrenia technologies and products.

Report scope

Schizophrenia Partnering 2010-2015 is intended to provide the reader with an in-depth understanding and access to schizophrenia trends and structure of deals entered into by leading companies worldwide.

This data driven report includes:

Trends in schizophrenia dealmaking in the biopharma industry since 2010
Access to summary headline, upfront, milestone and royalty data
Access to over 80 schizophrenia deals
The leading schizophrenia deals by value since 2010

In Schizophrenia Partnering 2010-2015, the available deals are listed by:

Headline value
Upfront payment value
Royalty rate value
Company A-Z
Industry sector
Stage of development at signing
Deal component type
Technology type

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.Schizophrenia Partnering 2010-2015 provides the reader with the following key benefits:

In-depth understanding of schizophrenia deal trends since 2010
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 80 actual schizophrenia deals entered into by the world’s biopharma companies since 2010
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Table Of Contents

Global Schizophrenia Partnering 2010-2015
Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in schizophrenia partnering

2.1. Introduction
2.2. Schizophrenia partnering over the years
2.3. Schizophrenia partnering by deal type
2.4. Schizophrenia partnering industry sector
2.5. Schizophrenia partnering by stage of development
2.6. Schizophrenia partnering by technology type

Chapter 3 - Average deal terms for schizophrenia

3.1 Introduction
3.2 Average deal terms for schizophrenia
3.3 Schizophrenia headline values with median calculation
3.4 Schizophrenia upfront values with median calculation
3.5 Schizophrenia milestone values with median calculation
3.6 Schizophrenia royalty rates with median calculation

Chapter 4 - Active schizophrenia dealmakers

4.1. Introduction
4.2 Most active schizophrenia dealmakers
4.3. Top schizophrenia deals by value
4.4 Big pharma deal activity
4.5 Big biotech deal activity

Chapter 5 - Schizophrenia dealmaking directory

5.1. Introduction
5.2. Company A-Z
5.3. By deal type
5.4. By industry sector
5.5. By stage of development
5.6. By technology type

Chapter 6 - Partnering resource center

6.1. Online partnering
6.2. Partnering events
6.3. Further reading on dealmaking

Appendices

Appendix 1 - Deal type definitions

About Wildwood Ventures

Current Partnering
Current Agreements
Recent report titles from Current Partnering
Order Form - Reports
Order Form - Subscription Access Products

Table of figures

Figure 1: Schizophrenia partnering since 2010
Figure 2: Schizophrenia dealmaking activity- 2010 to 2015
Figure 3: Schizophrenia partnering by deal type since 2010
Figure 4: Schizophrenia partnering by industry sector since 2010
Figure 5: Schizophrenia partnering by stage of development since 2010
Figure 6: Schizophrenia partnering by technology type since 2010
Figure 7: Schizophrenia deals with a headline value
Figure 8: Schizophrenia deals with upfront payment values
Figure 9: Schizophrenia deals with milestone payments
Figure 10: Schizophrenia deals with royalty rates, %
Figure 11: Top schizophrenia deals by value since 2010
Figure 12: Big pharma - top 50 - schizophrenia deals 2010 to 2015
Figure 13: Big pharma schizophrenia deal frequency - 2010 to 2015
Figure 14: Big biotech - top 50 - schizophrenia deals 2010 to 2015
Figure 15: Big biotech schizophrenia deal frequency - 2010 to 2015
Figure 16: Online partnering resources
Figure 17: Forthcoming partnering events
Figure 18: Deal type definitions

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024

  • $ 10995
  • Industry report
  • September 2016
  • by Global Data

PharmaPoint: Attention Deficit Hyperactivity Disorder (ADHD) - Global Drug Forecast and Market Analysis to 2024 Summary Attention deficit hyperactivity disorder (ADHD) is characterized by excessive levels ...

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

Substance Abuse Treatment Market: By Addiction Substances (Alcohol, Drugs, Cigarettes and Coffee); By Category (Alcohol, Nicotine Dependence Therapeutics, Drug Abuse Therapeutics) & By Region -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • September 2016
  • by Industry ARC

Alcoholism and drug dependence and addiction, known as substance use disorders and rehabilitation treatments are classified as substance abuse treatment. Some of the common symptoms of drug abuse are ...

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

Psychotherapeutic Drugs Market: By Type (Antipsychotics, Antidepressants, Antimaniacs, and Anxiety Drugs) & By Geography -Forecast (2016-2021)

  • $ 5250
  • Industry report
  • August 2016
  • by Industry ARC

Psychotherapeutic drugs are used to treat mental illnesses such as extreme mood swings, social withdrawal, long lasting depression, confused thinking, and suicidal thought. schizophrenia, bipolar disorder, ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.